CEUS is a safer, less expensive option for diagnosing focal liver disease.
Contrast-enhanced ultrasound (CEUS) is a safer, less costly option than CT and MRI when it comes to the accurate diagnosis of some types of liver cancer, according to recent research.
In a study published recently in Hepatoma Research, a team of investigators from the University of Calgary outlined some the unique advantages that CEUS offers when characterizing focal liver disease.
“CEUS provides for the determination of malignancy and allows excellent differential diagnosis of a focal liver mass,” said lead study author Stephanie Wilson, M.D., chair of the University of Calgary radiology department. “CEUS regularly resolves an indeterminate result on CT/MRI and is exceptional as a problem-solving tool in liver imaging.”
Routinely, she said, CEUS demonstrates comparable performance to CT and MRI with the characterization and prediction of malignancy.
To determine the details of CEUS’ capabilities, Wilson’s team analyzed the results of a multi-center trial that included 1,349 patients. The study, they said, revealed no statistically significant difference between CEUS and spiral CT in differentiating between benign and malignant liver tumors, as well as tumor specification. The team also examined a meta-analysis of 21 studies that showed CEUS has 88-percent sensitivity, 81-percent specificity, and a diagnostic odds ratio of 38.62. Those studies also showed no statistical differences between contrast-enhanced MRI and contrast-enhanced CT.
In particular, the team noted, CEUS offers several advantages:
Ultimately, the team concluded, CEUS can play a beneficial and effective role in liver cancer diagnostic imaging.
“CEUS has many similarities to contrast-enhanced CT/MRI, but also unique and valuable differences,” they said, “most showing the additional benefit of inclusion of CEUS with CT and MR for liver imaging.”